Peresolimab

N/A

Report date: 2025/12/05 20:00:50

Base Information

Drug NamePeresolimab
Drug Alias NameLY-3462817
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionProgrammed cell death protein 1 agonists
TargetsProgrammed cell death protein 1
Therapy Area/IndicationsAutoimmune DiseasesImmune System DiseasesPsoriasis +[9
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaCanadaUnited States +[15
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaIND
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Inactive CompaniesN/A
Active IndicationsArthritis, Rheumatoid
Inactive IndicationsAutoimmune DiseasesImmune System DiseasesPsoriasis +[8

Other Information

ATC CodeN/A
Related LinksN/A